NO911696L - Polypeptider. - Google Patents

Polypeptider.

Info

Publication number
NO911696L
NO911696L NO91911696A NO911696A NO911696L NO 911696 L NO911696 L NO 911696L NO 91911696 A NO91911696 A NO 91911696A NO 911696 A NO911696 A NO 911696A NO 911696 L NO911696 L NO 911696L
Authority
NO
Norway
Prior art keywords
csf
naturally occurring
residue
sequence replaced
polypeptides
Prior art date
Application number
NO91911696A
Other languages
English (en)
Norwegian (no)
Other versions
NO911696D0 (no
Inventor
Roger Camble
Heather Carr
David Timms
Anthony James Wilkinson
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909009623A external-priority patent/GB9009623D0/en
Priority claimed from GB909013773A external-priority patent/GB9013773D0/en
Priority claimed from GB909016215A external-priority patent/GB9016215D0/en
Priority claimed from GB919102799A external-priority patent/GB9102799D0/en
Application filed by Ici Plc filed Critical Ici Plc
Publication of NO911696D0 publication Critical patent/NO911696D0/no
Publication of NO911696L publication Critical patent/NO911696L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO91911696A 1990-04-30 1991-04-29 Polypeptider. NO911696L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909009623A GB9009623D0 (en) 1990-04-30 1990-04-30 Polypeptides
GB909013773A GB9013773D0 (en) 1990-06-20 1990-06-20 Polypeptides
GB909016215A GB9016215D0 (en) 1990-07-24 1990-07-24 Polypeptides
GB919102799A GB9102799D0 (en) 1991-02-11 1991-02-11 Polypeptides

Publications (2)

Publication Number Publication Date
NO911696D0 NO911696D0 (no) 1991-04-29
NO911696L true NO911696L (no) 1991-10-31

Family

ID=27450502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911696A NO911696L (no) 1990-04-30 1991-04-29 Polypeptider.

Country Status (23)

Country Link
US (1) US5416195A (cs)
EP (1) EP0459630B1 (cs)
JP (1) JPH06100593A (cs)
KR (1) KR910018406A (cs)
AT (1) ATE169336T1 (cs)
AU (1) AU644647B2 (cs)
BG (1) BG94328A (cs)
CA (1) CA2041454A1 (cs)
CS (1) CS125091A3 (cs)
DE (1) DE69129927T2 (cs)
DK (1) DK0459630T3 (cs)
ES (1) ES2118737T3 (cs)
FI (1) FI912086L (cs)
GB (1) GB9107846D0 (cs)
GR (1) GR3027590T3 (cs)
HU (1) HUT60769A (cs)
IE (1) IE911440A1 (cs)
IL (1) IL97993A0 (cs)
NO (1) NO911696L (cs)
NZ (1) NZ237974A (cs)
PT (1) PT97529A (cs)
TW (1) TW226022B (cs)
ZW (1) ZW4891A1 (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058398B2 (en) 1993-01-28 2011-11-15 Amgen Inc. Modified G-CSF polypeptide

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
AU7795094A (en) * 1993-09-15 1995-04-03 New York University Dna sequence which binds transcriptional regulatory proteins activated in response to various cytokines and uses thereof
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5573911A (en) * 1994-10-03 1996-11-12 Lifecodes Corp. Methods and materials for detecting autoimmune antibodies
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IT1285405B1 (it) * 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
KR100440460B1 (ko) * 1998-07-08 2004-10-08 주식회사유한양행 인체 과립구 콜로니 자극인자의 유전자, 재조합 벡터 및 형질 전환체 및 그들을 이용한 인체 과립구 콜로니 자극인자의 제조방법
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6627186B1 (en) 1999-01-06 2003-09-30 Xencor Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US7208473B2 (en) 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
KR100408429B1 (ko) * 2000-01-24 2003-12-06 한미약품 주식회사 유즙 중에 인간 과립구 콜로니 자극인자를 생산하는형질전환 흑염소
JP3544180B2 (ja) 2000-02-29 2004-07-21 ファイザー・プロダクツ・インク 安定化した顆粒球コロニー刺激因子
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
AU2001273385B2 (en) 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
WO2002020767A2 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
EP2305312B1 (en) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2003078461A1 (en) 2002-03-20 2003-09-25 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2198876B1 (en) 2003-10-24 2012-12-05 Nora Therapeutics, Inc. A method for reducing the likelihood of implantation failure in a subject
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
RU2007149238A (ru) 2005-06-01 2009-07-20 Максиджен Холдингз Лтд. (Ky) Пегилированные полипептиды гксф и способы их получения
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007102174A2 (en) 2006-03-06 2007-09-13 Cadila Healthcare Limited Process for preparing human g-csf
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
WO2009139784A1 (en) * 2008-05-13 2009-11-19 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
US9216206B2 (en) 2008-07-22 2015-12-22 Menogenix, Inc. Methods of treating symptoms associated with menopause and hormonal variations with G-CSF
PL2318029T3 (pl) * 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
ES2462517T3 (es) 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
PT2525787T (pt) 2010-01-19 2017-12-18 Hanmi Science Co Ltd Formulações líquidas para conjugado de g-csf de longa ação
EP2542574B1 (en) 2010-03-04 2017-08-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US8455218B2 (en) 2010-04-01 2013-06-04 Pfenex, Inc. Methods for G-CSF production in a Pseudomonas host cell
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CN102796197B (zh) * 2011-05-24 2013-12-25 杭州九源基因工程有限公司 一种hsa-gcsf突变体及其制备方法
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
EP3341025A4 (en) 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX BY USING A SPECIFIC ROLE OF AN IMMUNOMOBILIN FRAGMENT FOR LINKING
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
CA3255225A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California COMPOSITIONS AND METHODS OF GENETIC COMPLEMENTATION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
NO176799C (no) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68929566D1 (de) * 1988-05-13 2010-01-28 Amgen Inc Verfahren zur Isolierung und Reinigung von G-CSF
EP0377023B1 (en) * 1988-05-31 1995-02-15 Cetus Oncology Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058398B2 (en) 1993-01-28 2011-11-15 Amgen Inc. Modified G-CSF polypeptide

Also Published As

Publication number Publication date
KR910018406A (ko) 1991-11-30
FI912086A7 (fi) 1991-10-31
EP0459630B1 (en) 1998-08-05
CA2041454A1 (en) 1991-10-31
GB9107846D0 (en) 1991-05-29
AU644647B2 (en) 1993-12-16
JPH06100593A (ja) 1994-04-12
EP0459630A2 (en) 1991-12-04
ZW4891A1 (en) 1992-01-01
ATE169336T1 (de) 1998-08-15
CS125091A3 (en) 1992-02-19
AU7628491A (en) 1991-11-14
HUT60769A (en) 1992-10-28
HU911440D0 (en) 1991-11-28
NZ237974A (en) 1993-09-27
FI912086A0 (fi) 1991-04-30
TW226022B (cs) 1994-07-01
EP0459630A3 (en) 1992-10-21
DE69129927T2 (de) 1999-04-01
US5416195A (en) 1995-05-16
FI912086L (fi) 1991-10-31
DK0459630T3 (da) 1999-05-03
PT97529A (pt) 1992-01-31
BG94328A (bg) 1993-12-24
NO911696D0 (no) 1991-04-29
DE69129927D1 (de) 1998-09-10
IL97993A0 (en) 1992-06-21
IE911440A1 (en) 1991-11-06
GR3027590T3 (en) 1998-11-30
ES2118737T3 (es) 1998-10-01

Similar Documents

Publication Publication Date Title
NO911696L (no) Polypeptider.
ES2044952T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
ATE35152T1 (de) Plasmide und modifizierte staemme von vibrio cholerae, ihre herstellung und davon abgeleitete vakzine.
IL77293A (en) Stable,covalently-coupled,polysaccharide-protein conjugates comprising neutral polysaccharides and immunogenic proteins coupled through bigeneric spacers,methods for preparing them and pharmaceutical compositions containing them
AU557184B2 (en) Stabilized injectable solutions of piroxicam by addition of d-c-(-)-methylglucamine
CO5680455A2 (es) Composiciones de vacuna de neisserial que comprende una com binacion de antigenos
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
AU580973B2 (en) Novel polypeptides with an ``-amylase-inhibiting action, a process for their preparation, their use and pharmaceutical products
DK0726899T3 (da) Nye pyrazincarboxamidderivater, deres fremstilling og deres anvendelse i lægemidler
AU674378B2 (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
ES2056851T3 (es) Preparacion de terfenadina polimorficamente pura.
AU653371B2 (en) Pharmaceutical compositions
DK53285D0 (da) (-)-trans-4(4-fluorphenyl)-3-(4-methoxyphenoxy)-methylpiperidin, farmaceutisk acceptable syreadditionssalte heraf og farmaceutisk praeparat indeholdende samme
DK0614362T5 (da) Farmaceutiske præparater på basis af ebastin eller dermed analoge forbindelser
CA2085258A1 (en) Method for growth promotion of animals and powder compositions containing killed microbial cells of bacteria belonging to genus clostridium
AU6756287A (en) Nicorandil-containing preparation for injection
IT1269321B (it) Mutanti stabili della d-n- -carbamilasi
CA2080820A1 (fr) Derives azoiques, compositions pharmaceutiques et desinfectantes les contenant et leurs utilisations
ES8301244A1 (es) Procedimiento para la obtencion de derivados de sisomicina.
DK82787D0 (da) Triazolderivat og fremgangsmaade til fremstilling deraf samt plantevaekstregulerende middel indeholdende derivatet og derivatets anvendelse
IL76345A0 (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
ES8205218A1 (es) Un procedimiento para la preparacion de pirrolilpiperidinas utiles como agentes antidepresivo.
ES8100661A1 (es) Un procedimiento para la preparacion de 1-(3-bromo-isoxa- zol-5-il)-2-tercibutilaminoetanol
ATE194079T1 (de) Verwendung von einer suspension auf der basis von sucralfatgel als antazidum
ES485992A1 (es) Procedimiento para la obtencion de un fungicida a base de carboximidas y derivados sulfamidicos